During the corresponding time, Scorpius Holdings Inc saw a revenue deteriorated by -75.08 % year on year, sequentially revenue grew by 1.01 %. While revenue at the Scorpius Holdings Inc 's corporate clients
Scorpius Holdings Inc's Comment on Sales, Marketing and Customers
The company provides services to biotechnology, pharmaceutical, and university clients, supporting cell- and gene-based therapies as well as large molecule biologics. It specializes in CGMP biomanufacturing and quality control, utilizing American-made equipment, reagents, and materials to remain competitive for U.S. government contracts and biodefense projects. The company offers mammalian and microbial cell culture manufacturing, delivering fully integrated and customized biomanufacturing solutions from early preclinical development through commercial launch and supply. Its manufacturing facility is located in San Antonio, Texas, where it produces CGMP pharmaceutical-grade products and sources raw materials from third-party suppliers.
As the biotechnology sector pushes for increased domestic capacity and innovation, Scorpius Holdings, Inc. (NYSE American: SCPX) has made significant strides with the launch of its new business unit, Scorpius Ventures. This initiative aims to support up-and-coming biotech companies through a flexible equity-based onshoring model, which aligns closely with the s of the BIOSECURE Act. The legislation aims to bolster U.S. biosecurity and foster a sustainable domestic biotech ecosystem. Key Components of Scorpius Ventures Scorpius Ventures is designed to foster partnerships, bridging financial support and operational expertise for promising biotechnology firms. By combining fee-for-service approaches with equit...
In a strategic move set to reshape the landscape of biopharmaceutical production, Scorpius Holdings, Inc. (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO), has announced that it will launch its first current Good Manufacturing Practice (cGMP) mammalian manufacturing campaign at its cutting-edge San Antonio facility in the third quarter of 2024. This milestone underscores Scorpius s commitment to expanding its biomanufacturing capabilities and solidifies its position in the competitive sector of mammalian cell culture production for advanced biopharmaceuticals. Expanding Horizons: The San Antonio FacilityThe choice of San Antonio for this significant expansion co...
In the rapidly evolving biotechnology industry, companies constantly strive to enhance operational efficiencies and maintain regulatory compliance. One such company making significant strides is Scorpius Holdings. Recently, Scorpius Holdings has achieved a significant milestone with the successful validation of its Current Good Manufacturing Practice (cGMP) facility for microbial manufacturing. A crucial aspect of this accomplishment is the company’s strategic decision to transition to an internal environmental monitoring team, enhancing operating efficiency and ensuring consistent regulatory compliance. cGMP Facility Validation The validation of the cGMP facility marks a cornerstone in Scorpius Holdings ...
Scorpius Holdings Inc’s Comment on Sales, Marketing and Customers
The company provides services to biotechnology, pharmaceutical, and university clients, supporting cell- and gene-based therapies as well as large molecule biologics. It specializes in CGMP biomanufacturing and quality control, utilizing American-made equipment, reagents, and materials to remain competitive for U.S. government contracts and biodefense projects. The company offers mammalian and microbial cell culture manufacturing, delivering fully integrated and customized biomanufacturing solutions from early preclinical development through commercial launch and supply. Its manufacturing facility is located in San Antonio, Texas, where it produces CGMP pharmaceutical-grade products and sources raw materials from third-party suppliers.
Sources:
Scorpius Holdings inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Scorpius Holdings inc’s corporate clients.
For your research, we’ve provided 9 tables on Scorpius Holdings inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
